This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Constellation Brands to Divest Black Velvet Canadian Whisky
by Zacks Equity Research
Constellation Brands (STZ) is on track with wine and spirits business transformation strategy. The company signs an agreement with Heaven Hill Brands to divest Black Velvet Canadian Whisky.
Can European Expansion Aid Canopy Growth (CGC) Q1 Earnings?
by Zacks Equity Research
Canopy Growth's (CGC) recent acquisition of European companies will help it expand its production footprint into one of the most promising international regions.
Tilray to Report Earnings Today: Will It Top or Flop?
by Tirthankar Chakraborty
From global marijuana legalization to the rapidly increasing use of CBD as a wellness product, all of this should help Tilray witness an uptick in second-quarter revenues.
Canopy Growth Set to Acquire Beckley Canopy Therapeutics
by Zacks Equity Research
With the Beckley Canopy Therapeutics acquisition, Canopy Growth's (CGC) research and development endeavors would be expanding worldwide, thereby making the company a global pioneer in cannabinoid research.
Cannabis Expert Tim Seymour's Favorite Pot Stocks and ETF
by Neena Mishra
CNBC's cannabis expert Tim Seymour explains why he launched his own Cannabis ETF.
Cannabis Expert Tim Seymour's Favorite Pot Stocks and ETF
by Neena Mishra
CNBC's cannabis expert Tim Seymour explains why he launched his own Cannabis ETF.
ETFs in Focus as Consolidation Drives Marijuana Industry
by Sanghamitra Saha
Deals activity has been robust in the marijuana space, paving way for gains in these cannabis ETFs.
Can Cannabis Therapy Drive Canopy Growth's (CGC) Q1 Earnings?
by Zacks Equity Research
Canopy Growth (CGC) expects to deliver a strong first-quarter fiscal 2020 on solid performance by its cannabis therapy business.
The Zacks Analyst Blog Highlights: Canopy Growth and Tilray
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Canopy Growth and Tilray
2 Marijuana Stocks to Buy Heading into Q2 Earnings and Beyond
by Mitchell Moore
The marijuana industry is projected to grow at an annual rate of about 17% until it reaches $55.8 billion a year in 2025. The cannabis market has roughly tracked the S&P 500' s expansion in 2019 so far.
Canopy Growth Corporation (CGC) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) closed at $32.21 in the latest trading session, marking a -0.56% move from the prior day.
Will Canopy Growth Corporation (CGC) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Canopy Growth Corporation (CGC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Genesis Healthcare (GEN) This Season?
by Zacks Equity Research
Genesis Healthcare's (GEN) Q2 earnings should benefit from a stable census and reimbursement environment, effective cost management, improvement in therapy and staffing businesses.
American International (AIG) to Post Q2 Earnings: What???s Up?
by Zacks Equity Research
American International (AIG) Q2 earnings should benefit from increase in premiums and share buyback.
Canopy Growth Corporation (CGC) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Canopy Growth Corporation (CGC) closed at $33.20, marking a -0.9% move from the previous day.
4 Medical Product Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Here we discuss four medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
Canopy Growth Corporation (CGC) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Canopy Growth Corporation (CGC) closed at $34.86, marking a -1.76% move from the previous day.
Canopy Growth Corporation (CGC) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Canopy Growth Corporation (CGC) closed at $35.56, marking a +1.11% move from the previous day.
Implied Volatility Surging for Canopy Growth (CGC) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Canopy Growth (CGC) stock based on the movements in the options market lately.
Cronos to Acquire Apotex's Manufacturing Plant in Winnipeg
by Zacks Equity Research
Cronos (CRON) inks deal to acquire fermentation and manufacturing facility in Winnipeg, Canada, from Apotex Fermentation Inc.
CannTrust Falls as Health Canada Issues Non-Compliance Report
by Zacks Equity Research
Health Canada issues a non-compliance report on CannTrust (CTST) regarding its greenhouse facility in Pelham, Ontario, which is used for growing cannabis. Shares take a hit.
The Zacks Analyst Blog Highlights: GW, Scotts Miracle-Gro, Cronos, CannTrust and Canopy
by Zacks Equity Research
The Zacks Analyst Blog Highlights: GW, Scotts Miracle-Gro, Cronos, CannTrust and Canopy
5 Picks Ahead of Key Congressional Hearing on Marijuana Laws
by Nalak Das
Several economists and market researchers believe that the four bills may pave the way for marijuana ETFs, which are likely to attract billions of dollars in investment.
Canopy Growth Corporation (CGC) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Canopy Growth Corporation (CGC) closed at $39.47, marking a -1.72% move from the previous day.
Company News for Jul 5, 2019
by Zacks Equity Research
Companies In The News Are: TSLA, SYMC, AVGO, CGC, OMN